Toradol

Selected form

Ketorolac

Method of action: Analgesic, Analgetic, Anti-Inflammatory, Antipyretic, Nonsteroidal Anti-Inflammatory, Ophthalmologic Agent, Ophthalmologicals

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Toradol

This section provides a factual overview of the identity, composition, and general purpose of the medicine known commercially as Toradol, whose active compound is Ketorolac tromethamine.

Property	Description
Active ingredient	Ketorolac tromethamine
Form	Tablets, Injection (IV/IM), Nasal spray, Ophthalmic solution
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose	Potent relief of acute pain
Origin	Synthetic organic compound

What Type of Medicine is Ketorolac Tromethamine?

Ketorolac tromethamine is a powerful synthetic organic compound and a core member of the Nonsteroidal Anti-Inflammatory Drug (NSAID) pharmacological class. It is clinically recognized for its analgesic effects, distinguishing it from many other NSAIDs which are often chosen for long-term anti-inflammatory action. The chemical entity is a derivative of the pyrrolo-pyrrole group. It fundamentally works by blocking the production of chemical messengers, known as prostaglandins, which are responsible for transmitting pain and inflammation signals throughout the body.

What is Ketorolac's Primary Purpose and Benefit?

The primary general purpose of Ketorolac is the management of moderately severe acute pain, typically for short periods. This medication is valued because it provides pain relief comparable to certain narcotic agents. This characteristic allows it to function as an effective opioid-sparing agent in various clinical settings, such as the initial management of intense post-operative discomfort. As a non-opioid analgesic for acute pain, it provides significant, reliable relief during short-term use and serves as an established, non-narcotic option for controlling intense discomfort.

What Forms and Preparations of Ketorolac are Available?

As a single-component product, Ketorolac is prepared in several dosage forms to accommodate various routes of administration. The initial brand, Toradol, was strongly associated with its solution for injection (suitable for intravenous or intramuscular administration). Other major forms now include oral tablets, a nasal spray formulation, and an ophthalmic solution. The medication is included in lists of essential medicines, confirming the global recognition and necessity of its diverse presentations for essential acute pain management.

Regulatory References

What side effects are possible with Toradol?

Possible Side Effects and Safety Information

The official safety profile of Ketorolac tromethamine is defined by categories of adverse reactions and specific constraints documented in government regulatory materials, reflecting its classification as a potent Nonsteroidal Anti-Inflammatory Drug (NSAID).

Adverse effects are classified by frequency and physiological System-Organ Class (SOC) to provide a complete map of potential reactions.

Common and Rare Adverse Reactions

Side effects that are classified as common in regulatory reports (ge 1/100 to < 1/10) include gastrointestinal complaints such as nausea, dyspepsia, and pain, as well as nervous system effects like headache, dizziness, and somnolence. Reactions classified as rare (ge 1/10,000 to < 1/1,000) include severe events such as anaphylactic reactions, acute renal failure, and hepatic failure.

Documented Serious Adverse Reactions

Regulatory labels highlight the potential for serious adverse reactions, particularly those affecting the cardiovascular and gastrointestinal systems. These include potentially fatal events such as gastrointestinal ulceration, bleeding, and perforation, and the risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke). Severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also explicitly documented.

Safety Considerations and Restrictions

The risk of serious adverse events is officially stated to increase with higher doses and longer duration of use. Consequently, the regulatory use of Ketorolac tromethamine is constrained to the shortest possible duration for acute pain management. Official safety notes also specify increased risk for older adults and state contraindications for individuals with severe renal or hepatic impairment, or for use following Coronary Artery Bypass Graft (CABG) surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for an overdose of Ketorolac tromethamine (Toradol) is defined by specific, officially documented clinical manifestations and mandated emergency actions. Overdoses are typically managed with supportive measures as no specific antidotes are known.

Documented Overdose Presentations

Symptoms following acute overdose are generally reversible with supportive care, and include lethargy, drowsiness, nausea, vomiting, and epigastric pain. However, the official documentation lists severe outcomes that may occur, such as gastrointestinal bleeding, acute renal failure, hypertension, and coma.

Classification	Severe Outcomes Documented
Gastrointestinal	Peptic ulcers, erosive gastritis
Systemic	Acute renal failure, respiratory depression, coma

Emergency Response Statements

Patients should be managed by symptomatic and supportive care following a suspected overdose. Seek immediate emergency medical attention or contact the Poison Help line for any known or suspected ingestion. Procedures like activated charcoal administration may be suggested for large oral overdoses (defined as 5 to 10 times the usual dose) when intervention occurs within four hours of ingestion. Procedures such as hemodialysis are generally noted to be not useful for drug elimination.

Therapeutic Uses of Toradol

Toradol (ketorolac tromethamine) is a medication that may be part of symptomatic management for symptoms related to physical discomfort during acute, short-term episodes. Its therapeutic use is generally relevant in conditions where symptoms of physical discomfort are moderately severe.

This clinical application is generally relevant for addressing intense, acute pain. This medication is commonly used across clinical settings involving acute pain following surgical procedures, major traumatic events, and specialized painful episodes like renal colic or discomfort after oral surgery.

The Role of Opioid-Sparing Relief

A benefit of Toradol is that it helps manage symptoms related to physical discomfort at an intensity level generally associated with acute symptom management. It plays a role in pain management protocols where an opioid-sparing strategy is deemed appropriate. It supports patients during episodes of heightened discomfort, offering symptomatic relief when acute manifestations interfere with function.

Quick Fact: Relief for Acute Pain
Toradol is commonly used to help with symptoms related to physical discomfort during time-limited episodes.

Eligibility and Restrictions for Use

The eligibility for using Toradol (ketorolac tromethamine) is strictly defined by regulatory authorities due to the drug's potent nature and potential for serious risks, particularly with prolonged use. The medicine is officially established for short-term use only (typically a maximum of five days) in adults (generally 17 years and older).

Toradol is contraindicated and must not be used in several populations. These absolute exclusions include patients with a history of peptic ulcer disease or gastrointestinal (GI) bleeding, suspected or confirmed cerebrovascular bleeding or other bleeding disorders, and patients with advanced renal impairment (kidney failure). It is also prohibited for patients with a known NSAID hypersensitivity.

For age groups, systemic use is not recommended in pediatric patients (under 17) because safety and effectiveness are not established. Older adults (≥ 65 years) are permitted, but use requires caution and reduced dosages due to increased risk. Toradol is contraindicated during labor and delivery and in the third trimester of pregnancy, and its use is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Toradol (ketorolac tromethamine) has officially documented interaction patterns that establish specific restrictions and contraindications, primarily focusing on managing the risk of bleeding and altered drug exposure.

Contraindicated Combinations

Co-administration of ketorolac is formally prohibited with several medicine classes and substances as outlined in regulatory labeling. This restriction includes Aspirin and other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) due to the cumulative risk of serious NSAID-related side effects. The use of ketorolac is also contraindicated in patients receiving Anticoagulants (such as Warfarin), Pentoxifylline, or Probenecid because these combinations significantly increase the risk of serious bleeding or compromise the clearance of ketorolac, leading to elevated plasma concentrations.

Documented Pharmacodynamic and Exposure Effects

Ketorolac may antagonize the effect of certain blood pressure medications. It can reduce the antihypertensive effect of ACE Inhibitors/ARBs and the natriuretic effect of Diuretics. Co-administration with Lithium and Methotrexate is documented to potentially cause an elevation of their plasma levels due to a reduction in their renal clearance. For the oral formulation, taking it with a high-fat meal may delay and reduce the peak plasma concentration ( C max). The total combined duration of use for the injectable and oral tablet forms must not exceed five days.

Mechanism of Action

Molecular Target and Pathway Interruption

Toradol operates as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By binding to the active sites of these enzymes, the drug prevents the metabolism of arachidonic acid, thereby halting the synthesis of key eicosanoid mediators like prostaglandins and thromboxanes.

Systemic Downstream Modulation

The interruption of the COX pathway leads to changes in multiple physiological systems. Reduced production of prostaglandin E2 ( PGE2) dampens the sensitization of peripheral pain fibers (nociceptors), which results in a reduction of peripheral pain signaling. Furthermore, the reduction of other inflammatory prostaglandins alters vascular responses, which leads to a reduction in inflammation-related fluid exudation.

Non-Selective Mechanism Consequences

The drug's mechanism of non-selective COX inhibition extends to affecting systems outside of inflammation. By inhibiting COX-1 in platelets, the synthesis of thromboxane A2 ( TXA2) is reduced, a molecule crucial for platelet stickiness and the initiation of blood clotting. This leads to the physiological consequence of reduced platelet aggregation.

Dosage and Administration Information

How Toradol (Ketorolac Tromethamine) is Used

The usage of ketorolac tromethamine is governed by strict, time-limited protocols primarily concerning the route of administration, dosage, and duration. Systemic treatment is reserved exclusively for the short-term management of moderately severe acute pain.

Routes and Dose Sequence

Ketorolac is available for administration via intravenous (IV), intramuscular (IM), oral, nasal spray, and ophthalmic routes. For systemic acute pain relief, therapy must always begin with the IV or IM injection; the oral tablet is used only for continuation, never as the initial dose. IV bolus doses must be administered over a period of no less than 15 seconds.

Duration and Dosage Maximums

The total combined duration of systemic treatment (IV, IM, and oral) for acute pain must not exceed five days.

The standard adult multiple-dose regimen for IV or IM use is 30 mg every 6 hours, not to exceed a maximum total daily dose of 120 mg. The subsequent oral continuation dose is 10 mg every 4 to 6 hours, with a maximum daily limit of 40 mg for the oral form.

Population-Specific Adjustments

Dosage must be reduced for certain populations. For patients 65 years and older, those weighing less than 50 kg, or individuals with moderate renal impairment, the maximum total daily systemic dose (combined IV/IM/Oral) is reduced to 60 mg. Safety and efficacy for use in pediatric patients have not been established.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Toradol

Evidence Base for Acute Systemic Pain Management

Research exploring Ketorolac tromethamine has relied primarily on Randomized Controlled Trials (RCTs). Studies were conducted during periods of increased symptom activity, primarily involving adult patients for which research examined its use in contexts such as moderately severe, short-term pain, including post-surgical discomfort and acute episodes like renal colic (kidney stone pain) and discomfort after oral surgery.

The trials examined outcomes related to physical discomfort, with researchers monitoring changes in pain intensity scores over defined time intervals. Research also included the measurement of opioid consumption to understand patterns of use alongside the medicine. Findings describe patterns observed in the studies, including measured changes in reported pain levels and patterns of use of other analgesic options. Studies also reported that observed outcomes were short-term, reflecting the brief, time-limited nature of systemic research.

How Studies Measured Acute Pain Relief

Studies monitored outcomes related to systemic or functional imbalance to address the intense, temporary nature of the pain. Trials monitored how symptoms evolved in the observed populations by measuring how quickly a specific degree of relief was achieved. Studies monitored the need for supplemental analgesia (rescue medication) as an outcome reflecting daily functioning or activity level during acute phases. This research provides context but not individual predictions, helping to contextualize how patients reported their experience when using this medication for a short time.

Evidence for Topical Ophthalmic Applications

Research was conducted to evaluate the use of Ketorolac when applied topically as an eye drop solution. The evidence base here consists mainly of Randomized, vehicle-controlled clinical trials, where the active solution was compared to a non-active solution. Studies explored outcomes linked to inflammatory or irritative states, focusing on ocular pain and inflammation following specific procedures, such as cataract surgery or corneal refractive surgery. The research describes patterns in ocular pain scores and measured signs of inflammation monitored in the observed patient populations following their surgeries.

Key Limitations and Areas of Research Uncertainty

The evidence base for Ketorolac is characterized by its focus on short-term data. Follow-up durations were limited across the systemic pain trials. Long-term outcomes regarding pain management, functional recovery, or chronic pain development are not well characterized; the research data is limited by the short maximum treatment period. Research exploring specific groups, such as patients with pre-existing conditions (comorbidities) or certain pediatric patients, remains limited, and comparative evidence against all non-opioid options across every acute pain scenario is still emerging.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Toradol (FAQ)

Q: How does Toradol reduce platelet aggregation?

Toradol works by inhibiting an enzyme called Cyclooxygenase (COX). According to official product information, this inhibition reduces the production of a molecule known as thromboxane A2 (TXA2). Since TXA2 is crucial for helping platelets stick together and form a clot, this mechanism results in reduced platelet aggregation (clumping).

Q: What is the IV administration time for an injection?

Official labeling for the injectable solution specifies the time frame for administration. A bolus dose given intravenously (IV) must be pushed over a period of no less than 15 seconds. This is a procedural requirement outlined in the official product information.

Q: What pain conditions is Toradol typically used for?

Toradol is officially indicated for the short-term management of moderately severe acute pain. This typically includes pain levels that might otherwise require an opioid, such as discomfort following surgery. Official sources confirm it is not approved for long-term or chronic pain.

Q: Can Toradol be taken with a high-fat meal?

Official information indicates that taking the oral tablet form of Toradol alongside a high-fat meal may affect how your body processes the medicine. Specifically, it has been documented to delay the time it takes to reach the highest concentration of the drug in your blood, and it may also reduce the overall peak concentration (Cmax). For specific usage details, the prescribing healthcare professional is the best source of information.

Q: Can Toradol be used for fever?

Ketorolac tromethamine is officially indicated and approved for the treatment of moderately severe acute pain. According to the official regulatory documents, its approved use is not listed for the purpose of reducing fever.

Q: Can Toradol be prescribed for chronic pain?

No. The use of systemic Toradol (the tablet and injectable forms) is strictly limited to a maximum duration of five days. Because of this constraint, official labeling explicitly states that the drug is not indicated or approved for the chronic or long-term management of any pain condition.

Q: What is the typical onset of pain relief after taking Toradol?

Clinical studies reviewed by regulatory bodies provide information on how quickly the medication begins to work. For the injectable form, official study results indicate that pain relief (analgesia) has been observed to begin within 30 minutes after a dose is administered.

Q: What are the signs of an allergic reaction to Toradol?

Regulatory documents list severe hypersensitivity reactions, such as anaphylaxis, as a possible rare adverse effect. These serious allergic reactions are generally characterized by symptoms like swelling of the face, difficulty breathing, rash, or hives. If signs of a severe allergic reaction are observed, emergency medical help should be sought.

How should Toradol be stored and disposed of?

How to Store and Dispose of Toradol?

The official storage and disposal requirements for Toradol (ketorolac tromethamine) are mandated by regulatory bodies to maintain product quality and public safety.

Required Storage Conditions

Toradol must be stored at Controlled Room Temperature (20^circC to 25^circC, or 68^circF to 77^circF) and must be protected from light. It is essential to keep the medicine from freezing and do not refrigerate it. Tablets must remain in the original, tightly closed container and be stored away from excessive moisture.

Disposal and Safety

All forms of Toradol must be stored out of the sight and reach of children (store locked up). Disposal of unused or expired medicine must follow local regulations. Do not flush Toradol down the toilet or pour it down a drain. Use a drug take-back program or, if unavailable, mix the medicine with an undesirable substance and place it in a sealed container before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.